Arterial pulmonary hypertension, chronic thromboembolic pulmonary hypertension, pulmonary disease and/or hypoxia-related pulmonary hypertension
Conditions
Interventions
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Individuals aged 18 years or older; 2. Patients diagnosed with pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or pulmonary hypertension associated with lung diseases and/or hypoxia, in accordance with the diagnostic criteria outlined in the 2022 ERS/ESC Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension; 3. Participants who have provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with CTEPH who have been assessed by a multidisciplinary team as surgically eligible; 2. Presence of conditions such as upper limb arteriovenous thrombosis, limb deformities, or soft tissue injuries that may interfere with RIC intervention procedures; 3. Pregnant or breastfeeding women; 4. Life expectancy of less than three months; 5. Current participation in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduced glutathione(GSH), the oxidized-to-reduced glutathione ratio(GSH/GSSG);NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| TRV, TAPSE, S’, TRPG, EI;Pulmonary vascular resistance, mean pulmonary artery pressure, cardiac output, and mixed venous oxygen saturation;Arg, Cys, GSSG, NADH, NADP, NADPH, VC; | — |
Countries
China
Contacts
Public ContactQi Yang
Beijing Chao-Yang Hospital, Capital Medical University
Outcome results
None listed